Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
NNZ-2591 in Prader-Willi syndrome
Investor Information
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Home
>
Investor Information
>
Investor presentations, audio, video
Font Smaller
Font larger
Print Page
Investor presentations, audio, video
9-May-2022
Acadia Q1 2022 earnings call transcript
4-Apr-2022
Australian Financial Review article 4 Apr 2022
25-Feb-2022
Investor webinar, 25 February 2022
10-Dec-2021
AusBiz interview 8 December 2021
2-Jul-2021
Peak TV interview 2 July 2021
29-Jun-2021
MST Access Australian Micro & Small Caps Conference 2021 15 June 2021
29-Jun-2020
AGM Chairman's Address and CEO Presentation